Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review.
| Autor: | Czifrus E; Faculty of Medicine, Semmelweis University, Budapest, Hungary., Berlau DJ; Department of Pharmaceutical Sciences, School of Pharmacy, Regis University, Denver, CO. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Oct; Vol. 23 (10), pp. 1237-1247. Date of Electronic Publication: 2024 Aug 27. |
| DOI: | 10.1080/14740338.2024.2394578 |
| Abstrakt: | Introduction: Duchenne muscular dystrophy (DMD) is an X-linked genetic disorder characterized by progressive muscle degeneration and weakness, caused by mutations in the dystrophin gene. DMD has effects in early age with significantly shortened lifespan and deteriorated quality of life in the second decade, creating an urgent need to develop better therapeutic options. Corticosteroid medication therapy is an integral tool for the management of DMD and several therapeutic options have been recently approved for use. Areas Covered: A comprehensive literature search was completed to examine efficacy and safety profiles of the three corticosteroid medications available for use in DMD patients. The review presents information about the three agents through clinical trials, significant preclinical trials, and comparative studies. Expert Opinion: Managing DMD takes a multidisciplinary approach, although long-term corticosteroid therapy remains a significant therapeutic tool. Based on the available published studies, unequivocal comparison between the benefits of the three medications cannot yet be made. When selecting a medication for a patient, the decision-making process will most likely rely on the minor differences in the adverse effect profiles. Whichever medication is utilized will surely be a part of a larger regimen that includes other novel therapeutic agents. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|